Novartis' Growth Driver Tafinlar/Mekinist Picks Up New Melanoma, Thyroid Indications
New FDA labeling brings Tafinlar/Mekinist into adjuvant melanoma setting, but Bristol's competing Opdivo already has captured nearly 50% of the market and is approved regardless of genetic mutation.
You may also be interested in...
Lack of infrastructure for identifying mutations and access routes is holding back use of targeted medicines in children with cancer
Keeping Track: A CRL For Tlando, An Accelerated Approval For AndexXa, And A Burst Of Supplemental Approvals
The latest US drug development news and highlights from our Performance Tracker.
Novel oral anticoagulant Eliquis (apixaban) brought in $1.5bn in the first quarter and is set to overtake warfarin later this year. But Bristol remains on the defense on IO after a disappointing AACR.